Announcement on Subsidiary Obtaining Drug Registration Certificate

Renhe Pharmacy Co., Ltd.·June 15, 2026·2 pages

✨ AI Summary

Renhe Pharmaceutical's subsidiary, Jiangxi Yaodu Renhe Pharmaceutical, has received a Drug Registration Certificate from the National Medical Products Administration for Oseltamivir Phosphate Dry Suspension. This approval allows the company to produce and market the drug domestically, enhancing its competitiveness in the anti-infective sector. The company has invested approximately RMB 11 million in R&D for this project.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Renhe Pharmaceutical Co., Ltd. Announcement on Subsidiary Obtaining Drug Registration Certificate

The Company and all members of its board of directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or material omissions.

Jiangxi Yaodu Renhe Pharmaceutical Co., Ltd., a subsidiary of Renhe Pharmaceutical Co., Ltd., recently received a "Drug Registration Certificate" for Oseltamivir Phosphate Dry Suspension, approved and issued by the National Medical Products Administration. The relevant situation is hereby announced as follows:

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.